

John Zalcborg

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5565727/publications.pdf>

Version: 2024-02-01

104
papers

6,400
citations

236612

25
h-index

66788

78
g-index

106
all docs

106
docs citations

106
times ranked

7336
citing authors

#	ARTICLE	IF	CITATIONS
1	A comparison of outcomes and survival between Victoria and Denmark in lung cancer surgery: opportunities for international benchmarking. ANZ Journal of Surgery, 2022, 92, 1050-1055.	0.3	3
2	Clinical Trial Endpoints in Metastatic Cancer: Using Individual Participant Data to Inform Future Trials Methodology. Journal of the National Cancer Institute, 2022, 114, 819-828.	3.0	2
3	The association between quality care and outcomes for a real-world population of Australian patients diagnosed with pancreatic cancer. Hpb, 2022, 24, 950-962.	0.1	3
4	Opportunities and barriers for the use of Australian cancer registries as platforms for randomized clinical trials. Asia-Pacific Journal of Clinical Oncology, 2022, 18, 344-352.	0.7	4
5	Impacts of lung cancer multidisciplinary meeting presentation: Drivers and outcomes from a population registry retrospective cohort study. Lung Cancer, 2022, 163, 69-76.	0.9	6
6	Prognostic models to predict survival in patients with pancreatic cancer: a systematic review. Hpb, 2022, , .	0.1	1
7	Efficacy of anti-epidermal growth factor receptor agents in patients with RAS wild-type metastatic colorectal cancer≤ 70 years. European Journal of Cancer, 2022, 163, 1-15.	1.3	6
8	A snapshot of consumer engagement in clinical trials in Australia: results of a national survey of clinical trial networks and research organisations. Research Involvement and Engagement, 2022, 8, 3.	1.1	10
9	Chemotherapy in resectable or potentially resectable colon cancer with liver metastases. Expert Opinion on Pharmacotherapy, 2022, 23, 663-672.	0.9	3
10	A qualitative investigation of the supportive care experiences of people living with pancreatic and oesophagogastric cancer. BMC Health Services Research, 2022, 22, 213.	0.9	3
11	Metastatic Colorectal Cancer Outcomes by Age Among ARCAD First- and Second-Line Clinical Trials. JNCI Cancer Spectrum, 2022, 6, .	1.4	3
12	Functional Decline in the Cancer Patient: A Review. Cancers, 2022, 14, 1368.	1.7	29
13	Aspirin and the Risk of Colorectal Cancer According to Genetic Susceptibility among Older Individuals. Cancer Prevention Research, 2022, 15, 447-454.	0.7	5
14	The Management of Unresectable, Advanced Gastrointestinal Stromal Tumours. Targeted Oncology, 2022, 17, 95.	1.7	2
15	Systematic review of the predictors of health service use in pancreatic cancer.. American Journal of Cancer Research, 2022, 12, 622-650.	1.4	1
16	Development of melanoma clinical quality indicators for the Australian melanoma clinical outcomes registry (<sc>MelCOR</sc>): A modified Delphi study. Australasian Journal of Dermatology, 2022, , .	0.4	2
17	The SYMPTOM–upper gastrointestinal study: A mixed methods study exploring symptom appraisal and help–seeking in Australian upper gastrointestinal cancer patients. European Journal of Cancer Care, 2022, , .	0.7	1
18	Effect of Aspirin on Cancer Incidence and Mortality in Older Adults. Journal of the National Cancer Institute, 2021, 113, 258-265.	3.0	80

#	ARTICLE	IF	CITATIONS
19	The acceleration of ageing in older patients with cancer. <i>Journal of Geriatric Oncology</i> , 2021, 12, 343-351.	0.5	14
20	The EUS molecular evaluation of pancreatic cancer: A prospective multicenter cohort trial. <i>Endoscopic Ultrasound</i> , 2021, 10, 335-343.	0.6	4
21	Pre- and Postoperative Capecitabine Without or With Oxaliplatin in Locally Advanced Rectal Cancer: PETACC 6 Trial by EORTC GITCG and ROG, AIO, AGITG, BGDO, and FFCD. <i>Journal of Clinical Oncology</i> , 2021, 39, 17-29.	0.8	58
22	Ripretinib for the treatment of advanced gastrointestinal stromal tumor. <i>Therapeutic Advances in Gastroenterology</i> , 2021, 14, 175628482110081.	1.4	17
23	Impact of geography on prognostic outcomes of 21,509 patients with metastatic colorectal cancer enrolled in clinical trials: an ARCAD database analysis. <i>Therapeutic Advances in Medical Oncology</i> , 2021, 13, 175883592110205.	1.4	3
24	Excess mortality and undertreatment in elderly lung cancer patients: treatment nihilism in the modern era?. <i>ERJ Open Research</i> , 2021, 7, 00393-2020.	1.1	11
25	Effect of Follow-Up Surveillance After Curative-Intent Treatment of NSCLC on Detection of New and Recurrent Disease, Retreatment, and Survival: A Systematic Review and Meta-Analysis. <i>Journal of Thoracic Oncology</i> , 2021, 16, 784-797.	0.5	7
26	Measurement properties of the 12-item Short Form Health Survey version 2 in Australians with lung cancer: a Rasch analysis. <i>Health and Quality of Life Outcomes</i> , 2021, 19, 157.	1.0	18
27	Prognostic and Predictive Impact of Primary Tumor Sidedness for Previously Untreated Advanced Colorectal Cancer. <i>Journal of the National Cancer Institute</i> , 2021, 113, 1705-1713.	3.0	12
28	Genomic Risk Prediction for Breast Cancer in Older Women. <i>Cancers</i> , 2021, 13, 3533.	1.7	6
29	Clinical Benefit of Ripretinib Dose Escalation After Disease Progression in Advanced Gastrointestinal Stromal Tumor: An Analysis of the INVICTUS Study. <i>Oncologist</i> , 2021, 26, e2053-e2060.	1.9	19
30	Clinical Activity of Ripretinib in Patients with Advanced Gastrointestinal Stromal Tumor Harboring Heterogeneous KIT/PDGFRΑ Mutations in the Phase III INVICTUS Study. <i>Clinical Cancer Research</i> , 2021, 27, 6333-6342.	3.2	25
31	Factors involved in treatment decision making for women diagnosed with ductal carcinoma in situ: A qualitative study. <i>Breast</i> , 2021, 60, 123-130.	0.9	2
32	International variation in oesophageal and gastric cancer survival 2012–2014: differences by histological subtype and stage at diagnosis (an ICBP SURVMARK-2 population-based study). <i>Gut</i> , 2021, , gutjnl-2021-325266.	6.1	10
33	The short to medium term benefits of the Australian colorectal cancer screening program. <i>Medical Journal of Australia</i> , 2021, 214, 90-92.	0.8	0
34	FDG-PET Follow-up of Non-Small Cell Lung Cancer: Not Dead Yet. <i>Annals of Thoracic Surgery</i> , 2020, 109, 1624.	0.7	3
35	Intrigue: Phase III study of ripretinib versus sunitinib in advanced gastrointestinal stromal tumor after imatinib. <i>Future Oncology</i> , 2020, 16, 4251-4264.	1.1	43
36	Cancer history and risk factors in healthy older people enrolling in the ASPREE clinical trial. <i>Contemporary Clinical Trials</i> , 2020, 96, 106095.	0.8	8

#	ARTICLE	IF	CITATIONS
37	Real-world data for health technology assessment for reimbursement decisions in Asia: current landscape and a way forward. <i>International Journal of Technology Assessment in Health Care</i> , 2020, 36, 474-480.	0.2	33
38	The Victorian Lung Cancer Service Redesign Project: Impacts of a Quality Improvement collaborative on timeliness and management in lung cancer. <i>Internal Medicine Journal</i> , 2020, , .	0.5	3
39	Real-world treatment patterns, healthcare resource use and clinical outcomes of patients receiving second line therapy for advanced or metastatic gastric cancer. <i>BMC Gastroenterology</i> , 2020, 20, 133.	0.8	5
40	Comment on: “Hospital lung surgery volume and patient outcomes”™. <i>Lung Cancer</i> , 2020, 142, 138-139.	0.9	1
41	Ripretinib in patients with advanced gastrointestinal stromal tumours (INVICTUS): a double-blind, randomised, placebo-controlled, phase 3 trial. <i>Lancet Oncology</i> , The, 2020, 21, 923-934.	5.1	224
42	Developing an Australian multi-module clinical quality registry for gynaecological cancers: a protocol paper. <i>BMJ Open</i> , 2020, 10, e034579.	0.8	5
43	Barriers and enablers to the implementation of protocol-based imaging in pancreatic cancer: A qualitative study using the theoretical domains framework. <i>PLoS ONE</i> , 2020, 15, e0243312.	1.1	2
44	Towards a strategy for clinical quality registries in Australia. <i>Australian Health Review</i> , 2019, 43, 284.	0.5	9
45	Challenges of international oncology trial collaboration—a call to action. <i>British Journal of Cancer</i> , 2019, 121, 515-521.	2.9	17
46	What matters most to patients following percutaneous coronary interventions? A new patient-reported outcome measure developed using Rasch analysis. <i>PLoS ONE</i> , 2019, 14, e0222185.	1.1	2
47	Evaluation of Continuous Tumor-Size–Based End Points as Surrogates for Overall Survival in Randomized Clinical Trials in Metastatic Colorectal Cancer. <i>JAMA Network Open</i> , 2019, 2, e1911750.	2.8	6
48	Seven electrocardiographs for seven clinical research studies. <i>BMJ: British Medical Journal</i> , 2019, 365, l1720.	2.4	0
49	The 4th St. Gallen EORTC Gastrointestinal Cancer Conference: Controversial issues in the multimodal primary treatment of gastric, junctional and oesophageal adenocarcinoma. <i>European Journal of Cancer</i> , 2019, 112, 1-8.	1.3	23
50	Development of a binational thyroid cancer clinical quality registry: a protocol paper. <i>BMJ Open</i> , 2019, 9, e023723.	0.8	7
51	The Upper Gastrointestinal Cancer Registry (UGICR): a clinical quality registry to monitor and improve care in upper gastrointestinal cancers. <i>BMJ Open</i> , 2019, 9, e031434.	0.8	27
52	Peeling the Onion of Health Care Disparity in Lung Cancer. <i>Journal of Thoracic Oncology</i> , 2019, 14, e167-e168.	0.5	0
53	Monitoring quality of care for patients with pancreatic cancer: a modified Delphi consensus. <i>Hpb</i> , 2019, 21, 444-455.	0.1	20
54	Short-term outcome of emergency colorectal cancer surgery: results from Bi-National Colorectal Cancer Audit. <i>International Journal of Colorectal Disease</i> , 2019, 34, 63-69.	1.0	21

#	ARTICLE	IF	CITATIONS
55	Personalizing Survival Predictions in Advanced Colorectal Cancer: The ARCAD Nomogram Project. <i>Journal of the National Cancer Institute</i> , 2018, 110, 638-648.	3.0	90
56	Napabucasin versus placebo in refractory advanced colorectal cancer: a randomised phase 3 trial. <i>The Lancet Gastroenterology and Hepatology</i> , 2018, 3, 263-270.	3.7	121
57	Understanding and Communicating Measures of Treatment Effect on Survival: Can We Do Better?. <i>Journal of the National Cancer Institute</i> , 2018, 110, 232-240.	3.0	40
58	Age does not influence efficacy of ramucirumab in advanced gastric cancer: Subgroup analyses of REGARD and RAINBOW. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2018, 33, 814-824.	1.4	18
59	Exploring patient-reported outcomes following percutaneous coronary intervention: A qualitative study. <i>Health Expectations</i> , 2018, 21, 457-465.	1.1	22
60	Symptoms and feelings valued by patients after a percutaneous coronary intervention: a discrete-choice experiment to inform development of a new patient-reported outcome. <i>BMJ Open</i> , 2018, 8, e023141.	0.8	5
61	The value of participating in clinical trials: the whole is greater than the sum of its parts. <i>Medical Journal of Australia</i> , 2018, 209, 424.	0.8	2
62	Feasibility of 5-fluorouracil pharmacokinetic monitoring using the My-5FU PCMA ₂ system in a quaternary oncology centre. <i>Cancer Chemotherapy and Pharmacology</i> , 2018, 82, 865-876.	1.1	8
63	Consensus statement on essential patient characteristics in systemic treatment trials for metastatic colorectal cancer: Supported by the ARCAD Group. <i>European Journal of Cancer</i> , 2018, 100, 35-45.	1.3	29
64	Biosimilars are coming: ready or not. <i>Internal Medicine Journal</i> , 2018, 48, 1027-1034.	0.5	10
65	Patient-Reported Outcomes After Radiation Therapy in Men With Prostate Cancer: A Systematic Review of Prognostic Tool Accuracy and Validity. <i>International Journal of Radiation Oncology Biology Physics</i> , 2017, 98, 318-337.	0.4	10
66	Tools for Predicting Clinical and Patient-reported Outcomes in Prostate Cancer Patients Undergoing Androgen Deprivation Therapy: A Systematic Review of Prognostic Accuracy and Validity. <i>Clinical Genitourinary Cancer</i> , 2017, 15, 629-634.e8.	0.9	5
67	3rd St. Gallen EORTC Gastrointestinal Cancer Conference: Consensus recommendations on controversial issues in the primary treatment of pancreatic cancer. <i>European Journal of Cancer</i> , 2017, 79, 41-49.	1.3	43
68	Safety and tolerability of veliparib combined with capecitabine plus radiotherapy in patients with locally advanced rectal cancer: a phase 1b study. <i>The Lancet Gastroenterology and Hepatology</i> , 2017, 2, 418-426.	3.7	57
69	Optimum Tools for Predicting Clinical Outcomes in Prostate Cancer Patients Undergoing Radical Prostatectomy: A Systematic Review of Prognostic Accuracy and Validity. <i>Clinical Genitourinary Cancer</i> , 2017, 15, e827-e834.	0.9	16
70	An appraisal of analytical tools used in predicting clinical outcomes following radiation therapy treatment of men with prostate cancer: a systematic review. <i>Radiation Oncology</i> , 2017, 12, 56.	1.2	13
71	TOPGEAR: A Randomized, Phase III Trial of Perioperative ECF Chemotherapy with or Without Preoperative Chemoradiation for Resectable Gastric Cancer: Interim Results from an International, Intergroup Trial of the AGITC, TROG, EORTC and CCTG. <i>Annals of Surgical Oncology</i> , 2017, 24, 2252-2258.	0.7	186
72	An International Collaborative Standardizing a Comprehensive Patient-Centered Outcomes Measurement Set for Colorectal Cancer. <i>JAMA Oncology</i> , 2017, 3, 686.	3.4	94

#	ARTICLE	IF	CITATIONS
73	â€œMind the Gapâ€•Revisited. <i>Seminars in Oncology</i> , 2017, 44, 372-373.	0.8	1
74	Do all services provided as part of a clinical trial require research ethics and governance review?. <i>Internal Medicine Journal</i> , 2017, 47, 1197-1199.	0.5	0
75	Ten-Year Progression-Free and Overall Survival in Patients With Unresectable or Metastatic GI Stromal Tumors: Long-Term Analysis of the European Organisation for Research and Treatment of Cancer, Italian Sarcoma Group, and Australasian Gastrointestinal Trials Group Intergroup Phase III Randomized Trial on Imatinib at Two Dose Levels. <i>Journal of Clinical Oncology</i> , 2017, 35, 1713-1720.	0.8	148
76	Musicâ€™s Relevance for People Affected by Cancer: A Meta-Ethnography and Implications for Music Therapists. <i>Journal of Music Therapy</i> , 2016, 53, 398-429.	0.6	25
77	Second St. Gallen European Organisation for Research and Treatment of Cancer Gastrointestinal Cancer Conference: consensus recommendations on controversial issues in the primary treatment of rectal cancer. <i>European Journal of Cancer</i> , 2016, 63, 11-24.	1.3	73
78	Development of South Australian-Victorian Prostate Cancer Health Outcomes Research Dataset. <i>BMC Research Notes</i> , 2016, 9, 37.	0.6	4
79	The impact on health-related quality of life in the first 12 months: A randomised comparison of preoperative short-course radiation versus long-course chemoradiation for T3 rectal cancer (Trans-Tasman Radiation Oncology Group Trial 01.04). <i>European Journal of Cancer</i> , 2016, 55, 15-26.	1.3	45
80	Development and validation of prognostic nomograms for metastatic gastrointestinal stromal tumour treated with imatinib. <i>European Journal of Cancer</i> , 2015, 51, 852-860.	1.3	23
81	Accepting risk in the acceleration of drug development for rare cancers. <i>Lancet Oncology</i> , The, 2015, 16, e190-e194.	5.1	9
82	Regorafenib plus modified FOLFOX6 as first-line treatment of metastatic colorectal cancer: A phase II trial. <i>European Journal of Cancer</i> , 2015, 51, 942-949.	1.3	47
83	TOPGEAR: a randomised phase III trial of perioperative ECF chemotherapy versus preoperative chemoradiation plus perioperative ECF chemotherapy for resectable gastric cancer (an international,). <i>Tj ETQq1 1 0.7.84314 rg34 /Overlo</i>	1.3	34
84	An overview of experimental and investigational multikinase inhibitors for the treatment of metastatic colorectal cancer. <i>Expert Opinion on Investigational Drugs</i> , 2015, 24, 1307-1320.	1.9	7
85	Evaluation of efficacy and safety markers in a phase II study of metastatic colorectal cancer treated with aflibercept in the first-line setting. <i>British Journal of Cancer</i> , 2015, 113, 1027-1034.	2.9	34
86	Individual Patient Data Analysis of Progression-Free Survival Versus Overall Survival As a First-Line End Point for Metastatic Colorectal Cancer in Modern Randomized Trials: Findings From the Analysis and Research in Cancers of the Digestive System Database. <i>Journal of Clinical Oncology</i> , 2015, 33, 22-28.	0.8	87
87	Gastric cancer: past progress and present challenges. <i>Gastric Cancer</i> , 2015, 18, 205-209.	2.7	7
88	Broken doctorâ€™patient relationships: why won't they listen?. <i>Medical Journal of Australia</i> , 2014, 201, 347-349.	0.8	1
89	Regorafenib in gastrointestinal stromal tumors: clinical evidence and place in therapy. <i>Therapeutic Advances in Medical Oncology</i> , 2014, 6, 222-228.	1.4	19
90	The cost effectiveness of bevacizumab when added to capecitabine, with or without mitomycin-C, in first line treatment of metastatic colorectal cancer: Results from the Australasian phase III MAX study. <i>European Journal of Cancer</i> , 2014, 50, 535-543.	1.3	15

#	ARTICLE	IF	CITATIONS
91	Sound Continuing Bonds with the Deceased: The Relevance of Music, Including Preloss Music Therapy, for Eight Bereaved Caregivers. <i>Death Studies</i> , 2013, 37, 101-125.	1.8	34
92	Randomized Trial of Short-Course Radiotherapy Versus Long-Course Chemoradiation Comparing Rates of Local Recurrence in Patients With T3 Rectal Cancer: Trans-Tasman Radiation Oncology Group Trial 01.04. <i>Journal of Clinical Oncology</i> , 2012, 30, 3827-3833.	0.8	725
93	Dose optimization of tyrosine kinase inhibitors to improve outcomes in GIST. <i>Asia-Pacific Journal of Clinical Oncology</i> , 2012, 8, 43-52.	0.7	7
94	Delivering affordable cancer care in high-income countries. <i>Lancet Oncology</i> , The, 2011, 12, 933-980.	5.1	571
95	Adjuvant and Neoadjuvant Therapy for Gastric Carcinoma. <i>American Journal of Cancer</i> , 2006, 5, 111-121.	0.4	2
96	KIT mutations and dose selection for imatinib in patients with advanced gastrointestinal stromal tumours. <i>European Journal of Cancer</i> , 2006, 42, 1093-1103.	1.3	810
97	Outcome of patients with advanced gastro-intestinal stromal tumours crossing over to a daily imatinib dose of 800mg after progression on 400mg. <i>European Journal of Cancer</i> , 2005, 41, 1751-1757.	1.3	351
98	Evidence-Based Adjuvant Treatment of Resectable Pancreatic Adenocarcinoma. <i>American Journal of Cancer</i> , 2005, 4, 159-168.	0.4	0
99	Recent Advances in the Systemic Therapy of Metastatic Colorectal Cancer. <i>American Journal of Cancer</i> , 2005, 4, 15-34.	0.4	4
100	Progression-free survival in gastrointestinal stromal tumours with high-dose imatinib: randomised trial. <i>Lancet</i> , The, 2004, 364, 1127-1134.	6.3	1,561
101	Applications of Positron Emission Tomography in the Development of Molecular Targeted Cancer Therapeutics. <i>BioDrugs</i> , 2003, 17, 339-354.	2.2	20
102	Induction of insulin-like growth factor binding protein expression by ICI 182,780 in a tamoxifen-resistant human breast cancer cell line. <i>Breast Cancer Research and Treatment</i> , 1999, 55, 231-242.	1.1	25
103	Edrecolomab (Monoclonal Antibody 17-1A). <i>Drugs</i> , 1998, 56, 627-628.	4.9	1
104	Hormone replacement therapy and breast cancer. <i>Medical Journal of Australia</i> , 1998, 169, 399-399.	0.8	0